Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$310.55
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | BIIB Avg Daily Volume: 1,746,700
Last Update: 09/28/16 - 4:00 PM EDT
Volume: 0
YTD Performance: 1.37%
Open: $0.00
Previous Close: $310.55
52 Week Range: $223.02 - $333.65
Oustanding Shares: 219,120,762
Market Cap: 68,920,053,272
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 9 10 10
Moderate Buy 1 1 1 2
Hold 6 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.83 1.70 1.66 1.68
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 22.21
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
22.21 19.30 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
35.90% 14.06% 26.85%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.80 0.90 0.25
Net Income 22.20 1.60 0.37
EPS 24.00 1.60 0.38
Earnings for BIIB:
EBITDA 4.28B
Revenue 9.42B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $5.01 $5.06 $20.12 $20.89
Number of Analysts 19 19 18 19
High Estimate $5.26 $5.41 $20.67 $24.41
Low Estimate $4.58 $4.76 $19.66 $18.58
Prior Year $4.48 $4.50 $17.01 $20.12
Growth Rate (Year over Year) 11.85% 12.40% 18.28% 3.84%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Check out this biotech ETF, and Biogen, for plays on any recovery.
Bearish
Sep 06, 2016 | 7:02 AM EDT
BIIB was downgraded to Hold, Jefferies said. Valuation call, based on a $323 price target.
The leadership is quite stark.
Las Vegas Sands (LVS) continues to show strength after Bank of America/Merrill Lynch put out an optimistic note this morning about Macau gambling. Energy is weak in early trading. Oil has drifted back down to around $47 a barrel following its recent roughly 20% rally.

Bret Jensen Reporting for Duty Real Money Pro($)

Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Besides Tesla, Twitter and Biogen make good candidates.
There is a case for a low already being in place.
Deal rumors are deflating, but a takeover bid could reward holdouts.

Columnist Conversations

Join me after the close for a complimentary webinar as we'll talk about the recent market action and I'll take...
No big surprise here;  company never put up a profitable quarter from operations. Says it filed in order ...
Costco is working on its fourth straight decline.  Today the stock is taking out the initial September an...
People old enough to be on Medicare, but not yet collecting social security payments in 2016, may be in for an...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.